5-(2-bromoacetyl)-2-chloro-N,N-dimethylbenzenesulfonamide | 59815-99-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(2-bromoacetyl)-2-chloro-N,N-dimethylbenzenesulfonamide
• 英文别名: 2-bromo-4'-chloro-3'-dimethylsulfamoyl-acetophenone；2-Bromo-4'-chloro-3'-dimethylsulfamoylacetophenone
• CAS: 59815-99-5
• 化学式: C₁₀H₁₁BrClNO₃S
• 分子量: 340.625
• InChiKey: SJYNPNGXTMVCKZ-UHFFFAOYSA-N

物化性质

• 沸点：
  456.1±55.0 °C(Predicted)
• 密度：
  1.609±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(2-bromoacetyl)-2-chloro-N,N-dimethylbenzenesulfonamide 在 sodium borohydrid 作用下， 以 甲醇 、 乙醚 、 水 为溶剂， 生成 5-(2-bromo-1-hydroxyethyl)-2-chloro-N,N-dimethylbenzenesulfonamide
  参考文献：
  名称：

  Thiazolidine derivatives

  摘要：

  本发明涉及在4位具有羟基和3'-磺酰氨基-苯基取代基，在2位具有亚氨基，在1位具有脂肪族或环脂肪族取代基的噻唑烷衍生物。所述噻唑烷具有利尿活性。本发明还涉及制造所述化合物的方法。

  公开号：

  US04061761A1
• 作为产物：
  描述：

  4-chloro-3-(N,N-dimethylsulfamoyl)benzoic acid 在 吡啶 、 氯化亚砜 、 N,N-二甲基甲酰胺 、 copper(ll) bromide 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 氯仿 、 乙酸乙酯 为溶剂， 生成 5-(2-bromoacetyl)-2-chloro-N,N-dimethylbenzenesulfonamide
  参考文献：
  名称：

  Development of Benzenesulfonamide Derivatives as Potent Glutathione Transferase Omega-1 Inhibitors

  摘要：

  Glutathione transferase omega-1 (GSTO1-1) is an enzyme whose function supports the activation of interleukin (IL)-1 beta and IL-18 that are implicated in a variety of inflammatory disease states for which small-molecule inhibitors are sought. The potent reactivity of the active-site cysteine has resulted in reported inhibitors that act by covalent labeling. In this study, structure-activity relationship (SAR) elaboration of the reported GSTO1-1 inhibitor C1-27 was undertaken. Compounds were evaluated for inhibitory activity toward purified recombinant GSTO1-1 and for indicators of target engagement in cell-based assays. As covalent inhibitors, the k(inact)/K-I values of selected compounds were determined, as well as in vivo pharmacokinetics analysis. Cocrystal structures of key novel compounds in complex with GSTO1-1 were also solved. This study represents the first application of a biochemical assay for GSTO1-1 to determine k(inact)/K-I values for tested inhibitors and the most extensive set of cell-based data for a GSTO1-1 inhibitor SAR series reported to date. Our research culminated in the discovery of 25, which we propose as the preferred biochemical tool to interrogate cellular responses to GSTO1-1 inhibition.

  DOI：

  10.1021/acs.jmedchem.9b01391

文献信息

• Thiazolidine derivatives
  申请人：Hoechst Aktiengesellschaft

  公开号：US04061761A1

  公开（公告）日：1977-12-06

  The invention relates to thiazolidine derivatives having in 4-position a hydroxy group and a 3'-sulphamyl-phenyl substituent, in 2-position an imino group and in 1-position an aliphatic or cycloaliphatic substituent. Said thiazolidines have diuretic activity. The invention also relates to a process for the manufacture of said compounds.

  本发明涉及在4位具有羟基和3'-磺酰氨基-苯基取代基，在2位具有亚氨基，在1位具有脂肪族或环脂肪族取代基的噻唑烷衍生物。所述噻唑烷具有利尿活性。本发明还涉及制造所述化合物的方法。
• Thiazoline derivatives
  申请人：Hoechst Aktiengesellschaft

  公开号：US04346088A1

  公开（公告）日：1982-08-24

  Thiazoline derivatives of the general formula I ##STR1## wherein R.sup.1 to R.sup.7 have the specified meanings, physiologically acceptable acid addition salts thereof, processes for their preparation, pharmaceutical preparations based on these compounds and their use for acting on the serum lipoprotein spectrum. The invention moreover relates to compounds of the formulae ##STR2## wherein A, R, R.sup.1 to R.sup.7, Y and Z have the specified meanings.

  通式I的噻唑啉衍生物##STR1##，其中R.sup.1至R.sup.7具有指定的含义，其生理上可接受的酸盐，其制备方法，基于这些化合物的制药制剂以及它们用于作用于血清脂蛋白谱的用途。此外，本发明涉及以下通式的化合物##STR2##，其中A，R，R.sup.1至R.sup.7，Y和Z具有指定的含义。
• Thiazoline derivatives, processes for their preparation, their use and
  申请人：Hoechst Aktiengesellschaft

  公开号：US04421757A1

  公开（公告）日：1983-12-20

  Thiazoline derivatives of the formula I ##STR1## wherein R.sup.1 to R.sup.6 and Y have the meanings given, their physiologically tolerated salts, processes for their preparation, pharmaceutical preparations based on these compounds as well as their use as medicaments comprise the invention. In addition, intermediates are described.

  本发明涉及化合物I的噻唑啉衍生物：##STR1## 其中R.sup.1至R.sup.6和Y具有所给的含义，它们的生理耐受盐，制备它们的过程，基于这些化合物的制药制剂以及它们作为药物的用途。此外，还描述了中间体。
• DE2436263
  申请人：——

  公开号：——

  公开（公告）日：——
• Phenyliminothiazolinderivate, ihre Herstellung und Zwischenprodukte dafür, sie enthaltende pharmazeutische Präparate und deren Herstellung
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0023964B1

  公开（公告）日：1983-02-16